Moussali Anis, Cauchois Emi, Carvelli Julien, Hraeich Sami, Bouzana Fouad, Lesaux Audrey, Boucekine Mohamed, Bichon Amandine, Gainnier Marc, Fromonot Julien, Bourenne Jeremy
Réanimation des Urgences, Timone University Hospital APHM, Marseille, France.
Réanimation des Détresses Respiratoires et Infections Sévères, North University Hospital APHM, Marseille, France.
Front Med (Lausanne). 2022 May 13;9:880803. doi: 10.3389/fmed.2022.880803. eCollection 2022.
Aspiration pneumonia is the most common respiratory complication following out-of-hospital cardiac arrests (OHCA). Alpha-amylase (α-amylase) in pulmonary secretions is a biomarker of interest in detecting inhalation. The main goal of this study is to evaluate the performance of bronchoalveolar levels of α-amylase in early diagnosis of aspiration pneumonia, in patients admitted to intensive care unit (ICU) after OHCA.
This is a prospective single-center trial, led during 5 years (July 2015 to September 2020). We included patients admitted to ICU after OHCA. A protected specimen bronchial brushing and a mini-bronchoalveolar lavage (mini-BAL) were collected during the first 6 h after admission. Dosage of bronchial α-amylase and standard bacterial analysis were performed. Investigators confirmed pneumonia diagnosis using clinical, radiological, and microbiological criteria. Every patient underwent targeted temperature management.
88 patients were included. The 34% (30 patients) developed aspiration pneumonia within 5 days following admission. The 55% (17) of pneumonias occurred during the first 48 h. The 57% of the patients received a prophylactic antibiotic treatment on their admission day. ICU mortality was 50%. Median value of bronchial α-amylase did not differ whether patients had aspiration pneumonia (15 [0-94]) or not (3 [0-61], = 0,157). Values were significantly different concerning early-onset pneumonia (within 48 h) [19 (7-297) vs. 3 (0-82), = 0,047]. If one or more microorganisms were detected in the initial mini-BAL, median value of α-amylase was significantly higher [25 (2-230)] than in sterile cultures (2 [0-43], = 0,007). With an 8.5 IU/L cut-point, sensitivity and specificity of α-amylase value for predicting aspiration pneumonia during the first 2 days were respectively 74 and 62%. True positive and negative rates were respectively 44 and 86%. The area under the ROC curve was 0,654 (CI 95%; 0,524-0,785). Mechanical ventilation duration, length of ICU stay, and mortality were similar in both groups.
In our study, dosage of bronchial α-amylase was not useful in predicting aspiration pneumonia within the first 5 days after ICU admission for OHCA. Performance in predicting early-onset pneumonia was moderate.
吸入性肺炎是院外心脏骤停(OHCA)后最常见的呼吸并发症。肺分泌物中的α-淀粉酶(α-amylase)是检测吸入情况的一个有意义的生物标志物。本研究的主要目的是评估OHCA后入住重症监护病房(ICU)的患者支气管肺泡α-淀粉酶水平在吸入性肺炎早期诊断中的表现。
这是一项前瞻性单中心试验,历时5年(2015年7月至2020年9月)。我们纳入了OHCA后入住ICU的患者。在入院后的前6小时内进行了保护性标本支气管刷检和小型支气管肺泡灌洗(mini-BAL)。进行了支气管α-淀粉酶的定量分析和标准细菌分析。研究人员根据临床、影像学和微生物学标准确诊肺炎。每位患者都接受了目标体温管理。
纳入了88例患者。34%(30例)患者在入院后5天内发生了吸入性肺炎。55%(17例)的肺炎发生在最初的48小时内。57%的患者在入院当天接受了预防性抗生素治疗。ICU死亡率为50%。无论患者是否患有吸入性肺炎,支气管α-淀粉酶的中位数无差异(分别为15[0-94]和3[0-61],P = 0.157)。在早发性肺炎(48小时内)方面,数值有显著差异[19(7-297)对3(0-82),P = 0.047]。如果在最初的小型支气管肺泡灌洗中检测到一种或多种微生物,α-淀粉酶中位数显著高于无菌培养组[25(2-230)对2(0-43),P = 0.007]。以8.5 IU/L为切点,α-淀粉酶值在预测最初2天内吸入性肺炎的敏感性和特异性分别为74%和62%。真阳性率和真阴性率分别为44%和86%。ROC曲线下面积为0.654(95%CI;0.524-0.785)。两组的机械通气时间、ICU住院时间和死亡率相似。
在我们的研究中,支气管α-淀粉酶定量分析对预测OHCA后入住ICU的患者在入院后前5天内的吸入性肺炎并无帮助。预测早发性肺炎的表现中等。